NRF2-mediates HO-1 expression and ferroptosis resistance in KRAS mutant colorectal cancer cells, whereas combined cetuximab with RSL3 increases KEAP1 expression leading to inhibition of NRF2/HO-1 pathway [35]. Here, NFE2L2 is linked to colorectal cancer.